AzTrials
AzTrials

Bacteria in Breast MilkMIC-LAMA2NCT06037421

Metagenomic Analysis of Bacterial Microbiota in Breast Milk

An observational study of Bacteria in Breast Milk, run by Centre Hospitalier Sud Francilien at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to determine the extent to which bacteria in the breast milk microbiota represent an infectious risk for premature infants, by investigating whether they possess virulence genes, and if so, whether these are expressed or repressed. Read more about this study

Who is it for?
Ages 1 hour and older
Conditions the study is for
Bacteria in Breast Milk
What is being tested?
Human breast milk sampling, Saddle sampling and Skin sampling
How many people
120 participants
Where
1 siteFrance
Study dates
8 Sep 2025to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 hour and older
  • All sexes
  • Child, Adult, Older adult

Study population: Mother-infant pairs whose newborn(s) are being cared for in the CHSF's Neonatal Medicine and Intensive Care Unit.

Who may be able to join

  • Women of legal age who have given birth at the CHSF (or in another establishment) and whose newborn(s) are being cared for in the CHSF's Neonatal Medicine and Intensive Care Unit,
  • Women wishing to give their milk to their child,
  • Parents who have given their consent for the mother-child couple to take part in the study.

Who cannot join

  • Mother having received antibiotic therapy in the 3 months prior to delivery, except for those who received injectable antibiotic prophylaxis during delivery.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Didier LECOINTE, PharmD contact

33 1 61 69 76 69

didier.lecointe@chsf.fr

France1 site, 1 recruiting
  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France, 91106

    Didier LECOINTE, PharmD, 33 1 61 69 76 69, didier.lecointe@chsf.fr

    Benjalin QUERIN, Pharmacy intern, benjamin.querin@chsf.fr

    Recruiting

Other trials in France

About this study

The aim of this study is to determine the extent to which bacteria in the breast milk microbiota represent an infectious risk for premature infants, by investigating whether they possess virulence genes, and if so, whether these are expressed or repressed.

Read the detailed description

There are still many unknowns about the exact bacterial composition of breast milk, and the theoretical and real risks represented by its microbiota. In addition to determining the Total Aerobic Flora (TAF) and the Staphylococcus aureus presence, the most commonly isolated enterobacterales species identified by agar culture by the Prevention and Infection Control department are also among those potentially found in diagnostic samples: Enterobacter cloacae, Klebsiella pneumoniae, Klebsiella aerogenes, Klebsiella oxytoca and Escherichia coli. However, it is not yet known whether these are identical strains or not. It is therefore legitimate to ask whether there are any differences between the strains present in the microbiota of breast milk and those responsible for newborn infections.

Conventional methods for enumerating and identifying the bacteria making up the milk microbiota are not standardized, which makes it difficult to draw up a precise, multicentric inventory of its composition. It is therefore impossible to know whether exceeding a threshold value defined by expert consensus represents a real danger for newborns who must receive breast milk.

At the Centre National de Recherche en Génomique Humaine (CNRGH), a metagenomic sequencing approach makes it possible to study the microbiota using two complementary methodologies. Either by sequencing the genomes of organisms (bacteria, viruses, fungi, etc.) present in the environment to be analyzed (shotgun metagenomics), or by sequencing one or more genes specific to each bacterial species (targeted metagenomics). The gene that codes for 16S ribosomal RNA (rRNA) has sequence regions common to different bacterial species, as well as variable regions that can be used to distinguish the bacteria present in a sample.

A comparison of the composition of the bacterial microbiota in breast milk using conventional agar culture methods and metagenomic analysis methods would enable us to make progress in understanding its potential involvement in infectious pathologies in premature infants. It is in this scientific and medical context that a collaborative project was initiated for the first time between the departments of Neonatal Medicine and Intensive Care and of Prevention and Infection Control, and the CNRGH. This was a pilot study with the aim of perpetuating this collaboration, which combines scientific knowledge of the metagenome with the CNRGH's high-performance technological tools, as well as potential applications in the medical environment in the CHSF's care departments.

Being tested
Human breast milk sampling, Saddle sampling, Skin sampling, Saliva sampling, blood sampling
Keywords
Bacterial, newborn breast milk, neonates, infectious risk, virulence genes, agar culture methods, shotgun metagenomics, targeted metagenomics, microbiota

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Human breast milk samplingOther

    Human breast milk sampling

  • Saddle samplingOther

    Saddle sampling

  • Skin samplingOther

    Skin sampling

  • Saliva samplingOther

    Saliva sampling

  • blood samplingOther

    blood sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessing the potential pathogenic risk of certain bacteria in breast milk.

    Presence of virulence genes in strains of bacteria with pathogenic potential (S. aureus, K. aerogenes, E. coli, K. pneumoniae, K. oxytoca, E. cloacae) in breast milk.

    Measured: at day 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2023
  2. Study start8 Sep 2025
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06037421
Sponsor's protocol ID
2023-A01731-44
Acronym
MIC-LAMA2
Status last verified
Dec 2025
First submitted
6 Sep 2023
Last updated
16 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Bacteria in Breast Milk, run by Centre Hospitalier Sud Francilien at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Didier LECOINTE, PharmD (33 1 61 69 76 69, didier.lecointe@chsf.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessing the potential pathogenic risk of certain bacteria in breast milk. (time frame: at day 0). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in